SELLAS Life Sciences Completes Enrollment And Reports Positive Initial Data From Phase 2a Trial Of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising overall response rates and median overall survival improvements.
June 10, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising overall response rates and median overall survival improvements.
The positive initial data from the Phase 2a trial of SLS009, including high overall response rates and improved median overall survival, is likely to boost investor confidence and positively impact the stock price of SELLAS Life Sciences in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100